|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17.06.26 - 14:06
|
Gero Reaches $34M in Equity Funding to Turn the Physics of Aging Into Medicines (Business Wire)
|
|
|
Following a Chugai (Roche Group) collaboration with up to $250M in milestones in addition to royalties, and inspired by mammals that defy the rules of aging, Gero uses physics-first AI and human longitudinal data to develop medicines that substantially slow aging and treat age-related diseases.SINGAPORE & SAN FRANCISCO--(BUSINESS WIRE)--#AI--Gero, which previously secured a collaboration with Chugai Pharmaceutical, a member of the Roche Group, including an upfront payment and up to $250M in milestones in addition to royalties, today announced $17M in new financing, bringing total equity funding to $34M.
Gero combines longitudinal human data, AI, and a physics-based aging framework for therapeutic target identification and drug design. Gero's approach was born from a crucial but underappreciated observation: nature has already achieved dramatic slowing of aging and extremely long healthy life in several complex mammals. While in humans the risk of death roughly doubles every eight years after early adulth...
|
|
|
|
|
|
|
|
|
12.06.26 - 11:24
|
FDA grants priority review for Roche′s Tecentriq combo sBLA (PBR)
|
|
|
The application covers patients with stage III colon cancer characterised by deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) or microsatellite instability-high (MSI-H). The FDA is anticipated to make
The post FDA grants priority review for Roche's Tecentriq combo sBLA appeared first on Pharmaceutical Business review....
|
|
|
|
|
11.06.26 - 10:30
|
Nurix Therapeutics-Aktie: 700 Millionen Dollar von Roche – winkt hier Großes? (Sharedeals)
|
|
|
Die Aktie von Nurix Therapeutics konnte sich nach unserem Kauftipp im Juli letzten Jahres zwischenzeitlich fast verdoppeln und profitiert derzeit von einer Kombination aus klinischen Fortschritten und einer milliardenschweren Partnerschaft mit Roche. Während das Biotechunternehmen seine führende BTK-Degrader-Plattform in der Onkologie weiter vorantreibt, eröffnen sich zugleich neue Wachstumschancen in den Bereichen Immunologie und Neurologie. Roche-Partnerschaft […]
The post Nurix Therapeutics-Aktie: 700 Millionen Dollar von Roche – winkt hier Großes? first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
11.06.26 - 07:03
|
FDA grants Priority Review for Roche′s Tecentriq for a certain type of stage III colon cancer (GlobeNewswire EN)
|
|
|
Basel, 11 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) filing for adjuvant Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with chemotherapy in stage III deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) colon cancer, a type of tumour characterised by high mutation rates. The FDA has granted Priority Review and is expected to make a decision on the approval by 9 October 2026....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
